Investment for the future
CSL Behring had the pleasure of awarding the three best Master's Degrees in Biomedical Sciences at the University of Bern.
Results from Clinical Trial of COVID-19 Hyperimmune
CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune …
CSL COVID19 Update
CSL continues to provide medicines to patients around the world.
A Research Catalyst in Switzerland
A new partnership between CSL Behring and Biopôle takes shape, pairing the global biotech with one of the most dynamic life s…
Take the Rare Disease Day Quiz!
Test your knowledge about rare diseases, which affect more people than you think.
CSL Half Year Results 2020-21
CSL Delivers Net Profit of Over $ 1.8 Billion
What to Tell the Kids About COVID-19?
A walk to kindergarten with a group of 5-year-olds gave a CSL Behring scientist an idea for a timely children’s book.
What is a Phase III clinical trial?
A potential hyperimmune treatment for COVID-19 reaches a regulatory milestone in testing its efficacy and safety.
First Patient Enrolled to Evaluate Potential COVID-19 Hyperimmune Medicine
As co-leader, CSL Behring is very actively involved in this project. The product for the clinical trial phase 3 was manufactu…